Addressing gaps in the pharmaceutical market requires rigorous academic research and technical innovation.
External partners can work with us to advance their projects toward preclinical development.
Our researchers provide technical expertise, consultation, and in-depth knowledge to support every stage in the drug discovery pipeline.
External partners can draw on our multidisciplinary network of more than 400 researchers to design and advance projects through custom drug discovery pipelines.
Our expertise spans fundamental research, to hit-to-lead, and drug formulation, and incorporates the latest techniques and technologies.
We approach projects from a translational biology perspective: establishing fit-for-purpose drug screening cascades that incorporate AI, 3D cell cultures and multiomics.
Our work is informed by input from biotech, pharmaceutical and healthcare representatives, foregrounding clinical and commercial relevance from the early stages.
Our study of disease mechanisms at a molecular level enables the discovery of novel and relevant drug targets.
We use proteomic and genomic techniques, AI and advance computer-assisted platforms to pinpoint druggable targets to tackle clinical and commercial needs focusing on:
Computational and AI-based methodologies radically improve the efficiency of assay development and hit-to-lead activities.
Our researchers employ predictive platforms to capture accurate virtual models; improving screening, molecular docking and toxicity predictions.
We use a range of sophisticated methods to discover and validate hits.
We design, synthesise and optimise novel compounds.
Our academic expertise spans organic and inorganic chemistry, protein expression, and the use of new chemical and biochemical technologies.
Sophisticated non-animal models allow the efficacy and safety of new therapies to be tested with more accuracy.
Our researchers are developing new in vitro models that are highly reproducible and reliable for application in drug screening, imaging, data analysis and personlised medicine.
Since the rapid development of the COVID-19 vaccine, the use of mRNA and biologics to treat a host of rare and common disease has flourished.
We’re formulating and stabilising nanoparticle and protein-based vaccines and therapeutics.
To deliver accessible, patient-centric treatments, advancements in drug design must interlink with advancements in drug delivery.
Our pharmaceutical sciences experts are working on delivery methods that optimise how local and systemic diseases are treated.